Limits...
Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.

Braoudaki M, Lambrou GI, Vougas K, Karamolegou K, Tsangaris GT, Tzortzatou-Stathopoulou F - J Hematol Oncol (2013)

Bottom Line: Cytogenetic analysis was carried out by G- banding and interphase fluorescent in situ hybridization.Differential proteomic analysis was performed using two-dimensional gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.The differential expression of certain proteins was confirmed by Western blot analysis.

View Article: PubMed Central - HTML - PubMed

Affiliation: First Department of Pediatrics, University of Athens Medical School, Choremeio Research Laboratory, Thivon & Levadias 11527 Goudi-Athens, Greece.

ABSTRACT
The current study evaluated the differential expression detected in the proteomic profiles of low risk- and high risk- ALL pediatric patients to characterize candidate biomarkers related to diagnosis, prognosis and patient targeted therapy. Bone marrow and peripheral blood plasma and cell lysates samples were obtained from pediatric patients with low- (LR) and high-risk (HR) ALL at diagnosis. As controls, non-leukemic pediatric patients were studied. Cytogenetic analysis was carried out by G- banding and interphase fluorescent in situ hybridization. Differential proteomic analysis was performed using two-dimensional gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The differential expression of certain proteins was confirmed by Western blot analysis. The obtained data revealed that CLUS, CERU, APOE, APOA4, APOA1, GELS, S10A9, AMBP, ACTB, CATA and AFAM proteins play a significant role in leukemia prognosis, potentially serving as distinctive biomarkers for leukemia aggressiveness, or as suppressor proteins in HR-ALL cases. In addition, vitronectin and plasminogen probably contributed to leukemogenesis, whilst bicaudal D-related protein 1 could afford a significant biomarker for pediatric ALL therapeutics.

Show MeSH

Related in: MedlinePlus

Hierarchical clustering with Euclidean Distance of proteins classified with respect to patient risk (BMP/HR: Bone Marrow Plasma/High Risk, BMC: Bone Marrow Cells, PBC: Peripheral Blood Cells, PBP/HR: Peripheral Blood Plasma/High Risk, PBP/LR: Peripheral Blood Plasma/Low Risk, BMP/LR: Bone Marrow Plasma/Low Risk).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3717072&req=5

Figure 5: Hierarchical clustering with Euclidean Distance of proteins classified with respect to patient risk (BMP/HR: Bone Marrow Plasma/High Risk, BMC: Bone Marrow Cells, PBC: Peripheral Blood Cells, PBP/HR: Peripheral Blood Plasma/High Risk, PBP/LR: Peripheral Blood Plasma/Low Risk, BMP/LR: Bone Marrow Plasma/Low Risk).

Mentions: For further information on protein expression profile, hierarchical clustering analysis was used to identify patterns with respect to tissue of origin (FigureĀ 5). Samples were classified in four categories; BMP/HR and BMP/LR were classified in totally opposed groups, following the initial sampling taxonomy. On the other hand, BMC and PBC were grouped collectively as well as PBP/HR with PBP/LR. This indicates that BMC and PBC have very similar profiles on top of PBP/HR and PBP/LR. In particular the latter revealed no key differences in the peripheral blood setting, indicating that the pivotal microenvironment is that of BM.


Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.

Braoudaki M, Lambrou GI, Vougas K, Karamolegou K, Tsangaris GT, Tzortzatou-Stathopoulou F - J Hematol Oncol (2013)

Hierarchical clustering with Euclidean Distance of proteins classified with respect to patient risk (BMP/HR: Bone Marrow Plasma/High Risk, BMC: Bone Marrow Cells, PBC: Peripheral Blood Cells, PBP/HR: Peripheral Blood Plasma/High Risk, PBP/LR: Peripheral Blood Plasma/Low Risk, BMP/LR: Bone Marrow Plasma/Low Risk).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3717072&req=5

Figure 5: Hierarchical clustering with Euclidean Distance of proteins classified with respect to patient risk (BMP/HR: Bone Marrow Plasma/High Risk, BMC: Bone Marrow Cells, PBC: Peripheral Blood Cells, PBP/HR: Peripheral Blood Plasma/High Risk, PBP/LR: Peripheral Blood Plasma/Low Risk, BMP/LR: Bone Marrow Plasma/Low Risk).
Mentions: For further information on protein expression profile, hierarchical clustering analysis was used to identify patterns with respect to tissue of origin (FigureĀ 5). Samples were classified in four categories; BMP/HR and BMP/LR were classified in totally opposed groups, following the initial sampling taxonomy. On the other hand, BMC and PBC were grouped collectively as well as PBP/HR with PBP/LR. This indicates that BMC and PBC have very similar profiles on top of PBP/HR and PBP/LR. In particular the latter revealed no key differences in the peripheral blood setting, indicating that the pivotal microenvironment is that of BM.

Bottom Line: Cytogenetic analysis was carried out by G- banding and interphase fluorescent in situ hybridization.Differential proteomic analysis was performed using two-dimensional gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.The differential expression of certain proteins was confirmed by Western blot analysis.

View Article: PubMed Central - HTML - PubMed

Affiliation: First Department of Pediatrics, University of Athens Medical School, Choremeio Research Laboratory, Thivon & Levadias 11527 Goudi-Athens, Greece.

ABSTRACT
The current study evaluated the differential expression detected in the proteomic profiles of low risk- and high risk- ALL pediatric patients to characterize candidate biomarkers related to diagnosis, prognosis and patient targeted therapy. Bone marrow and peripheral blood plasma and cell lysates samples were obtained from pediatric patients with low- (LR) and high-risk (HR) ALL at diagnosis. As controls, non-leukemic pediatric patients were studied. Cytogenetic analysis was carried out by G- banding and interphase fluorescent in situ hybridization. Differential proteomic analysis was performed using two-dimensional gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The differential expression of certain proteins was confirmed by Western blot analysis. The obtained data revealed that CLUS, CERU, APOE, APOA4, APOA1, GELS, S10A9, AMBP, ACTB, CATA and AFAM proteins play a significant role in leukemia prognosis, potentially serving as distinctive biomarkers for leukemia aggressiveness, or as suppressor proteins in HR-ALL cases. In addition, vitronectin and plasminogen probably contributed to leukemogenesis, whilst bicaudal D-related protein 1 could afford a significant biomarker for pediatric ALL therapeutics.

Show MeSH
Related in: MedlinePlus